Research programme: ceNOS gene therapy - Crucell/BIOA&D
Latest Information Update: 16 Jun 2011
At a glance
- Originator BIOA&D; Crucell
- Mechanism of Action Gene transference; Nitric oxide donors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 30 May 2006 Preclinical trials in Cardiovascular disorders in Netherlands (unspecified route)